Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

PARP inhibitor olaparib slows progression of advanced prostate cancer

Prof Maha Hussain - Northwestern University Feinberg School of Medicine...

PARP inhibitor olaparib slows progression of advanced prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )

Comment: PARP inhibitors for advanced prostate cancer

Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain

Comment: PARP inhibitors for advanced prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019

Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer

Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA )

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and...

Prof George Sledge - Stanford Health Care, Stanford, USA

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy ( Prof George Sledge - Stanford Health Care, Stanford, USA )

Providing quality patient care and service using the Oncology Care Model

Dr Vedner Guerrier - Memorial Healthcare System, Hollywood, FL, USA

Providing quality patient care and service using the Oncology Care Model ( Dr Vedner Guerrier - Memorial Healthcare System, Hollywood, FL, USA )

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA...

Prof Hope Rugo - University of California, San Francisco, USA

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )

Ribociclib plus endocrine therapy improves survival in premenopausal patients...

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus...

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus chemotherapy in early breast cancer ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )

Breast cancer highlights from ASCO 2019

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Breast cancer highlights from ASCO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

More from ecancer